Data presented at WCLC showed combining RYBREVANT ®, lazertinib and chemotherapy may address the diverse resistance that emerges after disease progression on osimertinib SINGAPORE, Sept. 11, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.